Zacks Investment Research downgraded shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) from a buy rating to a hold rating in a research report report published on Monday.

According to Zacks, “AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of pain. The Company product candidates comprises: ARX-01 or the Sufentanil NanoTab PCA System; ARX-02 or the Sufentanil NanoTab BTP Management System; and ARX-03 or the Sufentanil/Triazolam NanoTab which are in their development stage. Its product ARX-01 is focused on acute post-operative pain, ARX-02 is focused on the treatment of cancer breakthrough pain and ARX-03 is focused on providing mild sedation, anxiety reduction, and pain relief to patients undergoing painful procedures in a physician’s office. AcelRx Pharmaceuticals, Inc. is headquartered in Redwood City, California. “

A number of other research analysts have also issued reports on ACRX. ValuEngine raised shares of AcelRx Pharmaceuticals from a strong sell rating to a sell rating in a research note on Tuesday, September 26th. HC Wainwright reissued a buy rating and set a $10.00 target price on shares of AcelRx Pharmaceuticals in a research note on Tuesday, October 3rd. Roth Capital set a $8.00 target price on shares of AcelRx Pharmaceuticals and gave the company a buy rating in a research note on Thursday, October 12th. Jefferies Group lowered shares of AcelRx Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, October 13th. Finally, Royal Bank of Canada reduced their target price on shares of AcelRx Pharmaceuticals from $6.00 to $5.00 and set an outperform rating for the company in a research note on Friday, October 13th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. The company has an average rating of Hold and a consensus target price of $6.21.

AcelRx Pharmaceuticals (ACRX) traded down $0.02 during trading on Monday, reaching $2.03. 195,000 shares of the company’s stock were exchanged, compared to its average volume of 413,950. The company has a debt-to-equity ratio of -0.43, a current ratio of 4.78 and a quick ratio of 4.71. The firm has a market cap of $100.68, a price-to-earnings ratio of -1.81 and a beta of 2.96. AcelRx Pharmaceuticals has a 52-week low of $1.55 and a 52-week high of $5.75.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last posted its earnings results on Thursday, November 9th. The specialty pharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.02). research analysts anticipate that AcelRx Pharmaceuticals will post -1.06 earnings per share for the current year.

In related news, Director Mark G. Edwards purchased 30,000 shares of AcelRx Pharmaceuticals stock in a transaction dated Tuesday, November 14th. The stock was bought at an average cost of $1.90 per share, with a total value of $57,000.00. Following the purchase, the director now owns 150,000 shares in the company, valued at approximately $285,000. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Corporate insiders own 28.10% of the company’s stock.

Several large investors have recently modified their holdings of ACRX. Perennial Advisors LLC acquired a new stake in shares of AcelRx Pharmaceuticals in the 3rd quarter worth approximately $138,000. Virtu KCG Holdings LLC lifted its stake in shares of AcelRx Pharmaceuticals by 600.9% in the 2nd quarter. Virtu KCG Holdings LLC now owns 118,675 shares of the specialty pharmaceutical company’s stock worth $255,000 after acquiring an additional 101,742 shares during the period. Geller Family Office Services LLC acquired a new stake in shares of AcelRx Pharmaceuticals in the 3rd quarter worth approximately $460,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of AcelRx Pharmaceuticals in the 2nd quarter worth approximately $530,000. 13.70% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://theolympiareport.com/2018/01/19/acelrx-pharmaceuticals-acrx-stock-rating-lowered-by-zacks-investment-research.html.

About AcelRx Pharmaceuticals

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Get a free copy of the Zacks research report on AcelRx Pharmaceuticals (ACRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.